{"hq_id":"hq-c-org-002107","name":"Nystatin","context":"human_adult","risk_level":"low","schema":"legacy","note":"Synthesis unavailable: compound lacks vectorizable regulatory classifications. Raw safety data returned.","data":{"risk_level":"low","summary":"Nystatin is a polyene macrolide antifungal antibiotic produced by Streptomyces noursei, discovered in 1950 and named after the New York State Department of Health laboratory where it was identified. Like amphotericin B, nystatin binds ergosterol and forms membrane pores, but it is too toxic for systemic use and is administered exclusively topically (oral suspension for oropharyngeal candidiasis, cream/ointment for cutaneous candidiasis, vaginal tablets). Poorly absorbed from GI tract (<5%), giving it an excellent safety profile for oral use — it transits the gut essentially unchanged, treating intestinal/oropharyngeal candidiasis locally. Adverse effects are minimal: nausea and GI discomfort with oral suspension, local irritation with topical use. No significant drug interactions. Nystatin has been in continuous clinical use for >70 years with remarkably low resistance rates — Candida resistance to nystatin remains rare (<5% globally). WHO Essential Medicine. Safe in pregnancy (FDA Category A/B depending on formulation). Available OTC in some countries.","source_refs":["aletheia_fungi_batch_2026"]},"meta":{"synthesis_version":"n/a","timestamp":"2026-07-27T02:35:27.622Z"},"_notice":"ALETHEIA output is reference data, not professional advice. Not a substitute for primary agency sources or qualified professionals. See https://aletheia.holisticquality.io/disclaimer.","_disclaimer_url":"https://aletheia.holisticquality.io/disclaimer","available_contexts":["human_adult"]}